CVS adds Lilly’s Foundayo and Zepbound to formularies, leveling GLP-1 market with Novo

CVS Caremark announced it will place Eli Lilly’s new oral GLP-1 drug Foundayo on its formulary starting June 1 and will restore the injectable Zepbound as a preferred option from Oct 1.

The change removes the preferential status Novo Nordisk’s Wegovy had enjoyed with CVS, putting Lilly’s products on equal footing with Novo across the three largest U.S. pharmacy benefit managers.

By covering both Foundayo and Zepbound, CVS could make the drugs available to millions of patients, although individual employers may still choose not to cover them.

Lilly’s shares rose about 6% after the announcement, reflecting investor optimism that the broader coverage expands the addressable market for its obesity treatments.